MiR-103 regulates hepatocellular carcinoma growth by targeting AKAP12

AKAP12/Gravin (A kinase anchor protein 12) belongs to the group of A-kinase scaffold proteins and functions as a tumor suppressor in some human primary cancers. While AKAP12 is found consistently downregulated in hepatocellular carcinoma (HCC), its involvement in hepatocarcinogenesis has not been fully elucidated. We identified targeting sites for miR-103 in the 3′-untranslated region (3′-UTR) of AKAP12 by bioinformatic analysis and confirm their function by a luciferase reporter gene assay. We reveal miR-103 expression to be inversely correlated with AKAP12 in HCC tissue samples and show that overexpressed miR-103 promotes cell proliferation and inhibits apoptosis by downregulating AKAP12 expression in HCC cell lines. On the other hand, repression of miR-103 suppresses proliferation and promotes apoptosis in HCC cells by increasing AKAP12. In xenografted HCC tumors, overexpression of AKAP12 suppresses tumor growth whereas overexpression of miR-103 enhances tumor growth while repressing AKAP12. Since the activation of telomerase is crucial for cells to gain immortality and proliferation ability, we investigated whether AKAP12 expression affected telomerase activity in HCC cells. Both AKAP12 overexpression and protein kinase Cα (PKCα) inhibition prevent nuclear translocation and phosphorylation of TERT and reduce telomerase activity in HCC cells. These findings indicate that miR-103 potentially acts as an oncogene in HCC by inhibiting AKAP12 expression and raise the possibility that miR-103 increases telomerase activity by increasing PKCα activity. Thus, miR-103 may represent a new potential diagnostic and therapeutic target for HCC treatment.     

miR-155-5p增强卵巢癌细胞UWB1.289对PARP抑制剂的敏感性

摘要 目的：探讨卵巢癌细胞UWB1.289中miR-155-5p对PARP抑制剂敏感性的影响及可能涉及的分子机制研究。方法：采用qRT-PCR技术检测miR-155-5p在有BRCA1/2突变和无BRCA1/2突变的卵巢癌组织及卵巢癌细胞中的表达情况。利用细胞转染、qRT-PCR以及Western Blot技术检测转染miR-155-5p模拟物和抑制剂的卵巢癌细胞UWB1.289中miR-155-5p的表达以及同源重组修复相关基因SIRT1、BRG1的表达。通过双荧光素酶报告基因实验验证miR-155-5p与SIRT1、BRG1之间的靶向性。运用CCK-8检测卵巢癌细胞UWB1.289中miR-155-5p对PARP抑制剂敏感性的影响。结果：与无BRCA1/2突变的卵巢癌组织及卵巢癌细胞相比,miR-155-5p在有BRCA1/2突变的卵巢癌组织及卵巢癌细胞中低表达。转染miR-155-5p模拟物可增加卵巢癌细胞UWB1.289中miR-155-5p的表达,同时降低同源重组修复相关基因SIRT1、BRG1的表达;转染miR-155-5p抑制剂可下调卵巢癌细胞UWB1.289中miR-155-5p的表达,同时增加SIRT1、BRG1的表达,进一步通过双荧光素酶报告基因实验证实miR-155-5p与SIRT1、BRG1存在特异性靶向结合序列。与对照组相比,干扰同源重组修复相关基因以及miR-155-5p过表达均可增强卵巢癌细胞UWB1.289对PARP抑制剂的敏感性。结论：miR-155-5p可能通过影响同源重组修复基因增强卵巢癌细胞UWB1.289对PARP抑制剂的敏感性。     

miR-106b-93-25簇对子宫内膜癌细胞的调控作用研究

目的:检测mi R-106b-93-25基因簇对子宫内膜癌细胞增殖及凋亡的影响,并探讨其机制。方法:q RT-PCR检测临床子宫内膜癌标本及癌旁正常组织中mi R-106b、mi R-93和mi R-25及其宿主基因MCM7的表达情况。将micro RNA及其拮抗剂转染ECC-1细胞后,MTT实验检测ECC-1细胞增殖情况,流式细胞术检测ECC-1细胞周期及细胞凋亡情况。荧光素酶报告系统验证mi R-106b和mi R-25分别直接调控p21和Bim。结果:临床标本子宫内膜癌组织与癌旁正常组织相比mi R-106b-93-25簇及其宿主基因MCM7的表达明显增高。mi R-106b-93-25簇能够促进ECC-1细胞增殖,减少凋亡。转染mi R-106b和mi R-93的细胞出现明显的S期阻滞,过表达mi R-25的细胞凋亡明显减少。mi R-106b-93-25簇通过抑制靶基因p21和Bim的表达,引起促增殖、抗凋亡作用。结论:mi R-106b-93-25簇能够促进子宫内膜癌细胞增殖,抑制凋亡,并使细胞发生S期阻滞。mi R-106b-93-25簇在子宫内膜癌的发生与发展中具有重要的作用。     

miR-155通过促进炎症因子释放参与脓毒症肠道屏障功能障碍的发生发展

摘要 目的：探讨miR-155在脓毒症致肠道功能障碍中的表达及作用。方法：（1）临床实验：以2022年5月至2022年8月入住新疆医科大学第一附属医院重症医学科的脓毒症患者和同期健康体检者为研究对象,根据急性胃肠损伤分级（AGI）将脓毒症患者分为AGI组和非AGI组。根据28 d生存情况分为存活组和死亡组,采用实时荧光定量反转录-聚合酶链反应（qRT-PCR）法前瞻性观察各组外周血miR-155的变化。（2）体内实验：将20只雄性S/D大鼠按照随机数字表法分为假手术组（sham组）和盲肠结扎穿孔术组（CLP组）,采用qRT-PCR及Western blot法检测miR-155、肠道紧密连接蛋白（ZO-1、claudin-1）的表达,ELISA法检测大鼠肠道组织中IL-1β、IL-6、IL-18的表达水平。(3)体外实验：培养人结直肠腺癌细胞（Caco-2）,并分为正常对照组(完全培养基培养48 h)、脂多糖组（完全培养基培养24 h后加入10 μg/mL LPS处理24 h）。采用qRT-PCR检测miR-155的表达。在倒置荧光显微镜下观察细胞形态的变化。采用CCK-8检测细胞活力。采用免疫荧光观察Caco-2细胞中紧密连接蛋白ZO-1分布的变化。并行细胞旁通透性实验,观察两组细胞旁通透性的变化。结果：（1）脓毒症组和健康对照组相比,脓毒症患者外周血miR-155较健康对照组明显升高,差异具有统计学意义（P<0.05）。AGI组患者外周血miR-155表达较非AGI组明显升高,差异具有统计学意义(P<0.05)。脓毒症死亡患者外周血miR-155表达显著升高(P<0.05)。（2）应用CLP模型进行体内动物实验,CLP组大鼠肠道组织miR-155表达较假手术组（sham组）明显升高。CLP组大鼠肠道紧密连接蛋白（ZO-1、claudin-1）较sham组下降,差异具有统 计学意义(P<0.05)。ELISA结果提示,CLP大鼠肠道组织中IL-1β、IL-6、IL-18水平较sham组显著升高（P<0.05）,且肠道组织中miR-155水平与IL-1β、IL-6、IL-18呈正相关（r=0.542,r=0.906,r=868,P<0.05）。（3）与正常对照组相比,经LPS处理后细胞形态破坏、细胞间紧密连接破坏、细胞活力减弱、细胞旁通透性增加。结论：脓毒症发生时伴有肠道屏障功能障碍,miR-155在脓毒症肠道屏障功能障碍中表达升高,并可能通过促进炎症因子的释放参与脓毒症肠道屏障功能障碍的发生发展。miR-155异常表达对脓毒症患者早期肠道功能障碍诊断及预后的评估具有重要价值,可作为脓毒症早期肠道损伤诊断及预后情况的重要指标。     

外泌体lncRNA-MIR100HG/miR-100表达变化与胃癌临床病理特征、无疾病进展生存率的相关性

摘要 目的：探究胃癌患者血清外泌体长链非编码RNA-MIR100HG（lncRNA-MIR100HG）及微小核糖核酸-100（miR-100）表达情况,并分析其与患者临床病理特征和无疾病进展生存率之间的相关性。方法：收集60例胃癌患者和60例良性疾病患者,提取外泌体,检测lncRNA-MIR100HG/miR-100的表达情况并进行组间比较。采用Pearson相关分析lncRNA-MIR100HG与miR-100表达水平的相关性,应用单因素卡方检验分析与胃癌患者临床病理特征相关性,采用Kaplan-Meier生存分析lncRNA-MIR100HG/miR-100表达情况与无疾病进展生存率。结果：（1）胃癌组患者血清lncRNA-MIR100HG显著高于,miR-100相对表达水平显著低于胃良性疾病组（P<0.05）;（2）Pearson相关分析结果显示血清lncRNA-MIR100HG和miR-100存在显著负相关关系（r=-0.483,P<0.05）;（3）单因素卡方检验分析结果显示：胃癌患者血清lncRNA-MIR100HG相对表达水平与肿瘤大小、分化程度、肿瘤浸润深度、临床分期、淋巴结转移和远处转移相关,血清miR-100相对表达水平与肿瘤大小、分化程度、临床分期和淋巴结转移相关（P<0.05）;（4）血清lncRNA-MIR100HG、miR-100低水平表达胃癌患者PFS显著长于高水平患者（χ²=37.371,P＜0.05）,miR-100高水平表达胃癌患者PFS显著长于低水平患者（χ²=28.631,P＜0.05）。结论：胃癌患者血清外泌体lncRNA-MIR100HG/miR-100表达水平与肿瘤大小、肿瘤浸润深度、临床分期等病理特征相关,lncRNA-MIR100HG高表达与miR-100低表达可能提示胃癌患者预后越差。     

喉鳞状细胞癌组织miR-1207-5p、miR-186-5p表达水平与PI3K/Akt信号通路、临床病理特征和预后的关系

摘要 目的：探讨喉鳞状细胞癌（LSCC）组织miR-1207-5p、miR-186-5p表达水平与磷脂酰肌醇3-激酶/蛋白激酶B（PI3K/Akt）信号通路、临床病理特征和预后的关系。方法：选取2017年1月至2020年1月南充市中心医院收治的120例LSCC患者,取手术切除的LSCC组织和癌旁组织。检测miR-1207-5p、miR-186-5p、PI3K mRNA、Akt mRNA表达。患者出院后随访3年,统计总生存（OS）和无复发生存（RFS）情况。分析miR-1207-5p、miR-186-5p与PI3K、Akt的相关性以及影响LSCC患者预后的因素。结果：LSCC组织miR-1207-5p、miR-186-5p表达低于癌旁组织（P＜0.05）,PI3K mRNA、Akt mRNA表达高于癌旁组织（P＜0.05）。LSCC组织miR-1207-5p、miR-186-5p表达与PI3K mRNA、Akt mRNA表达呈负相关（P＜0.05）。肿瘤直径≥1 cm、低分化、TNM分期Ⅲ期、颈部淋巴结转移LSCC组织中miR-1207-5p、miR-186-5p表达低于肿瘤直径＜1 cm、中高分化、TNM分期Ⅰ～Ⅱ期、无颈部淋巴结转移（P＜0.05）。miR-1207-5p低表达、miR-186-5p低表达LSCC患者3年总生存（OS）率和无复发生存（RFS）率低于miR-1207-5p高表达、miR-186-5p高表达LSCC患者（P＜0.05）。多因素COX回归分析显示TNM III期、颈部淋巴结转移是LSCC患者复发和死亡的危险因素（P＜0.05）,高miR-1207-5p、高miR-186-5p是保护因素（P＜0.05）。结论：LSCC组织中miR-1207-5p和miR-186-5p表达均下调,与LSCC恶性病理特征、PI3K/Akt信号通路激活以及低生存率有关。     

Formation of Paul-Bunnell antibodies by cultures of lymphocytes from infectious mononucleosis.

Short-term cultures of peripheral blood lymphocytes obtained from 20 infectious mononucleosis patients 2–4 weeks after the onset of the disease were studied for formation of heterophile antibodies. In studying pooled supernatant fluids of lymphocytes from three patients cultured for 3–20 days, lytic antibodies for red blood cells of bovine (BRBC) and sheep (SRBC) origin were demonstrated. These hemolysins were shown to be of IgM nature and Paul-Bunnell specificity. Subsequently, plaque-forming cell (PFC) assays were performed with lymphocyte cultures of 15 patients. Significant numbers (60–750/2 × 10⁷ cells) of PFC secreting antibodies against BRBC were demonstrated in lymphocyte cultures of 12 patients. The number of PFC apparently reached its peak after 5 to 10 days of culturing. No or a very few PFC were observed in the lymphocytes that were not cultured or in lymphocytes cultured for 3 weeks or longer. Lymphocyte cultures prepared in a similar fashion from normal individuals or patients suffering from sore throat and submandibular lymphadenopathy of other than infectious mononucleosis origin did not produce PFC. Production of lytic zones by antibodies to BRBC secreted by PFC was inhibited by preincubation of lymphocytes of infectious mononucleosis patients with solubilized Paul-Bunnell antigen but not with other heterophile antigens, indicating that antibodies involved in the PFC formation are of Paul-Bunnell specificity. An increased number of PFC against BRBC were obtained in two of three lymphocyte cultures after cultivation with BRBC or solubilized Paul-Bunnell antigen.     

MiR-92a regulates brown adipocytes differentiation,mitochondrial oxidative respiration,and heat generation by targeting SMAD7

Brown adipocytes are rich in mitochondria and linked to the body's blood fat levels and obesity. MiR-92a is negatively correlated with the activity of brown adipocytes. This study aimed to explore the mechanism of miR-92a on brown adipocytes. The expression of miR-92a in C2C12 cell was detected by a quantitative real-time-polymerase chain reaction (qRT-PCR). C2C12 cells were induced to brown adipocytes. The direct target gene of miR-92a was determined using the dual-luciferase reporter assay. Brown adipocytes were treated with isoprenaline (Iso) and transfected by miR-92a inhibitor and siSMAD7. The expression of heat-producing genes and adipose differentiation genes related to brown adipocytes were detected by qRT-PCR and Western blot analysis. The expression of SMAD7, p-SMAD2, and p-SMAD3 were detected using Western blot analysis. The mitochondrial content was measured by mitotracker fluorescent staining. MiR-92a inhibitor significantly decreased the expression of miR-92a in C2C12 cells. MiR-92a inhibitor could upregulate the expression of Ucp1, Cox7a1, Elovl3, Ppargc1α, PPARγ, and FABP4, and its effect on Ucp1 was increased after the treatment of isoprenaline. Moreover, miR-92a inhibitor increased mitochondrial content, oxygen consumption rate (OCR) and the expression of SMAD7 and suppressed the expressions of p-SMAD2 and p-SMAD3, whereas miR-92a directly targeted SMAD7 to exert its inhibitory effects. SiSMAD7 reversed the effects of the inhibitor on heat-producing genes, mitochondrial content, OCR and the expressions of SMAD7, p-SMAD2, and p-SMAD3 in brown adipocytes. Blocking miR-92a might promote brown adipocytes differentiation, mitochondrial oxidative respiration, and thermogenesis by targeting SMAD7 to inhibit the expressions of p-SMAD2 and p-SMAD3.     

miR-26a抑制转化生长因子beta诱导的韧带成纤维细胞增殖

目的:研究miR-26a对转化生长因子-β(Transforming growth factor-β,TGF-β)诱导的韧带成纤维细胞增殖的影响。方法:原代分离大鼠肩周韧带成纤维细胞,通过免疫荧光鉴定细胞纯度,应用脂质体细胞转染miRNA模拟物的方式过表达miR-26a,定量PCR的方法检测miR-26a模拟物的过表达效率,CCK8法检测细胞增殖能力的变化,生物信息学预测的方法分析miR-26a可能的作用靶基因。结果:免疫荧光检测发现原代分离细胞中,Vimentin阳性细胞在90%以上;转染miR-26a模拟物后,细胞内miR-26a水平显著高于阴性对照组(P<0.05);TGF-β刺激明显促进韧带成纤维细胞生长(P<0.01),而miR-26a则对TGF-β诱导的韧带成纤维细胞增殖具有显著的抑制作用(P<0.01);生物信息学预测显示SMAD1/4、EIF4G2、PTEN和MARK1可能是miR-26a影响细胞增殖的作用靶基因。结论:miR-26a可抑制TGF-β诱导的韧带成纤维细胞增殖。